External validation of a therapeutic window for risperidone in children with autism spectrum disorder
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70130 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Rebecca A Hermans und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Risperidone, Drug Monitoring, Antipsychotic Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organization for Health Research and Development (ZonMW), German Federal Institute of Drugs and Medical Devices (BfArM), ZonMw.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Although risperidone is an effective pharmacological intervention for managing disruptive behaviour in children with autism spectrum disorder, it may induce metabolic side effects. This study aimed to externally validate the population pharmacokinetic (popPK) model and the therapeutic window of 3.5–7 ng/mL of risperidone and 9‐OH‐risperidone, developed with data of the SPACe Study. For this external validation, data from the German Therapeutic Drug Monitoring (TDM) Service and TDM‐VIGIL Study was used in nonlinear mixed‐effects modelling to evaluate popPK model performance and in receiver operating curve analyses to define the therapeutic window. Population predictions of the popPK model showed underprediction for risperidone concentrations, but individual predictions were fairly accurate. Receiver operating curve analyses resulted in a therapeutic window of 5.0–8.0 ng/mL. The popPK model seems suitable for use in TDM. Because the current analysis included only a few low sum trough concentrations, we suggest maintaining the therapeutic window of 3.5–7.0 ng/mL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Rotterdam Clinical Pharmacometrics Group, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wurzburg, Germany.
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Freiburg, Germany.
ORCID-Profile: Rebecca A Hermans, Birgit C P Koch, Stefanie Fekete, Brenda C M de Winter
Förderung
- Netherlands Organization for Health Research and Development (ZonMW)
- German Federal Institute of Drugs and Medical Devices (BfArM)
- ZonMw
Zitieren
APA
Hermans, R. A., Bruens, K., Egberts, K. M., Koch, B. C. P., Dierckx, B., Hillegers, M. H. J., Romanos, M., Taurines, R., Fekete, S., Eisenecker, K., Clement, H. W., Fleischhaker, C., & de Winter, B. C. M. (2025). External validation of a therapeutic window for risperidone in children with autism spectrum disorder. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70130
Vancouver
Hermans RA, Bruens K, Egberts KM, Koch BCP, Dierckx B, Hillegers MHJ, et al. External validation of a therapeutic window for risperidone in children with autism spectrum disorder. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70130
BibTeX
@article{Hermans2025,
author = {Hermans, Rebecca A and Bruens, Kathalijne and Egberts, Karin M and Koch, Birgit C P and Dierckx, Bram and Hillegers, Manon H J and Romanos, Marcel and Taurines, Regina and Fekete, Stefanie and Eisenecker, Khatia and Clement, Hans-Willi and Fleischhaker, Christian and de Winter, Brenda C M},
title = {External validation of a therapeutic window for risperidone in children with autism spectrum disorder},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70130}
}
EUVIMED